synthetic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-21. Numbers and descriptions here follow the published literature rather than marketing material.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
== Digestibility == Hemp protein, when untreated, is more digestible compared to soy protein. Heat pre-treatment at temperatures above 80 °C may improve the digestibility of both hemp and soy protein, but in untreated (unheated) form hemp protein is more readily digested than the soy one. Dehulled hemp seeds (also known as hemp nuts, hemp kernels or hemp hearts) have a protein digestibility corrected amino acid score (PDCAAS) of 0.66, with lysine being the limiting amino acid (digestibility of 92.1%). With its gluten content as low as 4.78 ppm, hemp is attracting attention as a gluten-free (<20 ppm) food material. Hemp protein is sold in bulk as a powder, in various forms, such as hempseed meal, hemp protein concentrates, and hemp protein isolates. It generally has greenish hue due to the natural pigments in the hemp plant, but the color can vary depending on the specific processing methods used. Unflavored hemp protein powder is commonly available, that is, no additional flavoring is added to the hemp protein, which is usually described as earthy or nutty.
{\displaystyle {\begin{aligned}u(y,z)&={\frac {G}{2\mu }}(y+z)(\pi -y)-{\frac {G}{\pi \mu }}\sum _{n=1}^{\infty }{\frac {1}{\beta _{n}^{3}\sinh(2\pi \beta _{n})}}\left\{\sinh[\beta _{n}(2\pi -y+z)]\sin[\beta _{n}(y+z)]-\sinh[\beta _{n}(y+z)]\sin[\beta _{n}(y-z)]\right\},\quad \beta _{n}=n+{\tfrac {1}{2}},\\[6pt]Q&={\frac {G\pi ^{4}}{12\mu }}-{\frac {G}{2\pi \mu }}\sum _{n=1}^{\infty }{\frac {1}{\beta _{n}^{5}}}\left[\coth(2\pi \beta _{n})+\csc(2\pi \beta _{n})\right].\end{aligned}}}
Absence of antibodies in patients with diagnoses of an autoimmune thyroid in their past would always be suspicious for development to SAT even in the presence of a normal TSH because there is no known recovery from autoimmunity. For clinical interpretation of laboratory results it is important to acknowledge that TSH is released in a pulsatile manner resulting in both circadian and ultradian rhythms of its serum concentrations.
Sources: en.wikipedia.org
Tirofiban, inhibitor of the glycoprotein IIb/IIIa, used as a cardiovascular drug Maraviroc, inhibitor of the CCR5-gp120 interaction, used as anti-HIV drug. Venetoclax Lifitegrast Sotorasib Adagrasib Experimental inhibitors in drug development include:
== Advantages == Ionization of the substrate is very efficient as it occurs at atmospheric pressure, and thus has a high collision frequency. Additionally, APCI considerably reduces the thermal decomposition of the analyte because of the rapid desolvation and vaporization of the droplets in the initial stages of the ionization. This combination of factors most typically results in the production of ions of the molecular species with fewer fragmentations than many other ionization methods, making it a soft ionization method. Another advantage to using APCI over other ionization methods is that it allows for the high flow rates typical of standard bore HPLC (0.2–2.0 mL/min) to be used directly, often without diverting the larger fraction of volume to waste. Additionally, APCI can often be performed in a modified ESI source. The ionization occurs in the gas phase, unlike ESI, where the ionization occurs in the liquid phase. A potential advantage of APCI is that it is possible to use a nonpolar solvent as a mobile phase solution, instead of a polar solvent, because the solvent and molecules of interest are converted to a gaseous state before reaching the corona discharge needle. Because APCI involves a gas-phase chemistry, there is no need to use special conditions such as solvents, conductivity, pH for LC. APCI appears to be more versatile LC/MS interface and more compatible with reversed-phase LC than ESI.
=== Antimicrobial activity === In plant Oldenlandia affinis it generates antimicrobial cyclic peptides which are important for defence against pathogens in plants. The herb has been used in native African medicine to accelerate childbirth.
=== Image === Bush's upbringing in West Texas, his accent, his vacations to his Texas ranch, and his penchant for country metaphors contribute to his folksy, American cowboy image. "I think people look at him and think John Wayne", said Piers Morgan, editor of the British Daily Mirror. Bush has been parodied by the media, comedians, and other politicians. Detractors tended to cite linguistic errors made by Bush during his public speeches, which are colloquially referred to as Bushisms. In contrast to his father, who was perceived as having trouble with an overarching unifying theme, Bush embraced larger visions and was seen as a man of larger ideas who took significant risks. Tony Blair wrote in 2010 that the caricature of Bush as being dumb is "ludicrous" and that Bush is "very smart". In an interview with Playboy, The New York Times columnist David Brooks said Bush "was 60 IQ points smarter in private than he was in public. He doesn't want anybody to think he's smarter than they are, so he puts on a Texas act."
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.